Robert M. Elashoff
Affiliations: | University of California, Los Angeles, Los Angeles, CA |
Area:
Biostatistics BiologyGoogle:
"Robert Elashoff"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Volkmann ER, Tashkin DP, Roth MD, et al. (2020) The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosis. Seminars in Arthritis and Rheumatism. 50: 963-967 |
| Kim GHJ, Tashkin DP, Lo P, et al. (2019) Using transitional changes on HRCT to monitor the impact of cyclophosphamide or mycophenolate on systemic sclerosis-related interstitial lung disease. Arthritis & Rheumatology (Hoboken, N.J.) |
| Volkmann ER, Tashkin DP, Sim M, et al. (2019) Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II. The Journal of Rheumatology |
| Volkmann ER, Tashkin DP, Sim M, et al. (2018) Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. Annals of the Rheumatic Diseases |
| Garon EB, Siegfried JM, Stabile LP, et al. (2018) Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 123: 91-98 |
| Shino MY, Weigt SS, Li N, et al. (2017) The prognostic importance of CXCR3 chemokine during organizing pneumonia on the risk of chronic lung allograft dysfunction after lung transplantation. Plos One. 12: e0180281 |
| Shino MY, Weigt SS, Li N, et al. (2017) The prognostic importance of bronchoalveolar lavage fluid CXCL9 during minimal acute rejection on the risk of chronic lung allograft dysfunction. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons |
| Volkmann ER, Tashkin DP, Li N, et al. (2017) Mycophenolate versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II. Arthritis & Rheumatology (Hoboken, N.J.) |
| Volkmann E, Sim M, Tashkin D, et al. (2017) OP0124 Treatment with cyclophosphamide for systemic sclerosis-related interstitial lung disease does not improve survival after 12 years of follow up Annals of the Rheumatic Diseases |
| Volkmann ER, Tashkin DP, Roth MD, et al. (2016) Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease. Arthritis Research & Therapy. 18: 305 |